Sirolimus

西罗莫司

Report date: 2026/05/02 20:00:18
NMEFirst In Class

Base Information

Drug NameSirolimus
Drug Alias Name雷帕霉素sirolimussirolimusum西罗莫斯PNP-sirolimus +[42] 
ClassificationSmall molecules > Heterocyclic drugsSmall molecules > Molecular Glue
Mechanisms of ActionmTOR Complex 2 inhibitorsMammalian target of Rapamycin (mTORC1) inhibitors
TargetsMammalian target of Rapamycin (mTORC1)mTOR Complex 2
Therapy Area/IndicationsRejection of organ transplantationRejection of renal transplantationDiabetic macular oedema +[129] 
Global Approved IndicationsRejection of organ transplantationRejection of renal transplantationLeiomyoma
Approved Indications in ChinaRejection of renal transplantation
Original Approved Country/TerritoryUnited States
Original Approved Date1999/09/15
Country/TerritoryCzechiaBelgiumCanada +[42] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesPfizer Inc
China Registration ClassN/A

Develop Information

Active CompaniesSanten IncConcept Medical IncDermatology Specialties Limited Partnership +[48] 
Inactive CompaniesDana-Farber Cancer InstituteWyeth LlcTransderm Inc +[44] 
Active IndicationsRejection of organ transplantationRejection of renal transplantationCoronavirus Disease 2019 (COVID-19) +[47] 
Inactive IndicationsDiabetic macular oedemaBone marrow transplant rejectionGraft Rejection +[82] 

Other Information

ATC CodeL04AH01S01XA23
Related LinksWikipediaDrugBankKEGG